Allergan vs. Alembic: Generic LUMIGAN® Patent Dispute Dismissed
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Allergan, Inc. v. Alembic Pharmaceuticals |
| Case Number | 1:25-cv-06986 (E.D.N.Y.) |
| Court | U.S. District Court for the Eastern District of New York |
| Duration | Dec 19, 2025 – Jan 30, 2026 42 days |
| Outcome | Procedural Dismissal — Without Prejudice |
| Patents at Issue | |
| Accused Products | Alembic’s generic version of LUMIGAN® 0.01% (bimatoprost ophthalmic solution) |
Case Overview
The Parties
⚖️ Plaintiff
A global pharmaceutical leader and subsidiary of AbbVie, recognized for its ophthalmic portfolio, including LUMIGAN® for glaucoma treatment.
🛡️ Defendant
An India-headquartered generic drug manufacturer with a significant U.S. market presence, active in paragraph IV patent challenges.
The Patent at Issue
At the center of this dispute is **U.S. Patent No. 7,851,504 B2** (Application No. 11/083,261), directed to pharmaceutical compositions comprising bimatoprost. The ‘504 patent protects formulation-level innovations relevant to the 0.01% concentration of LUMIGAN®—a lower-concentration version developed by Allergan to reduce side effects while maintaining therapeutic efficacy compared to the earlier 0.03% formulation.
- • US 7,851,504 B2 — Pharmaceutical compositions comprising bimatoprost (LUMIGAN® 0.01% formulation)
Developing a generic pharmaceutical?
Check if your formulation might infringe this or related patents before launch.
The Verdict & Legal Analysis
Outcome
The case was resolved through **consensual dismissal without prejudice** of all claims asserted in the pleadings. Per the parties’ agreement, all allegations and averments contained in the action were dismissed without prejudice—meaning Allergan retains the right to reassert its infringement claims in a future action should circumstances warrant. No damages were awarded, and no injunctive relief was granted or denied on the merits. The specific basis of termination and any underlying settlement terms were not disclosed in the public case record.
Key Legal Issues
The official verdict cause is categorized as an Infringement Action under 35 U.S.C. § 271(e)(2), the statutory framework governing ANDA patent litigation established by the Hatch-Waxman Act. The compressed 42-day timeline, with no reported substantive motions or rulings, strongly suggests a negotiated resolution rather than a judicial determination on the merits.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in ophthalmic drug formulation. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View relevant pharmaceutical patents in this technology space
- See which companies are most active in ophthalmic drug patents
- Understand formulation claim construction patterns
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Formulation patents on established ophthalmic drugs
Key Formulation Patents
In ophthalmic drug space
Design-Around Options
Available for concentration and excipient variants
✅ Key Takeaways
Dismissal without prejudice in Hatch-Waxman actions preserves plaintiff’s future enforcement rights—a strategically important distinction.
Search related case law →The 42-day case duration suggests pre-litigation or early-stage resolution; document any licensing or consent terms carefully.
Explore precedents →U.S. Patent No. 7,851,504 B2 remains active and enforceable; monitor for future assertions against other ANDA filers.
View Patent Details →FTO analysis for ophthalmic generics must address formulation and concentration-level claims, not solely active ingredient patents.
Start FTO analysis for my product →The LUMIGAN® 0.01% patent landscape remains active litigation territory—proceed with regulatory and commercial planning accordingly.
Explore the patent landscape →Frequently Asked Questions
The case involved U.S. Patent No. 7,851,504 B2 (Application No. 11/083,261), a pharmaceutical composition patent covering formulations relevant to LUMIGAN® 0.01% (bimatoprost ophthalmic solution).
The parties mutually agreed to dismiss all claims without prejudice. No merits-based ruling was issued. A dismissal without prejudice preserves Allergan’s right to bring future claims under the same patent.
The rapid resolution reinforces the viability of early negotiated outcomes in Hatch-Waxman litigation and highlights the continued importance of formulation-level patent protection for branded ophthalmic drugs facing generic competition.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- PACER – Case No. 1:25-cv-06986
- USPTO Patent Center
- Google Patents – US 7,851,504 B2
- Cornell Legal Information Institute — 35 U.S.C. § 271(e)(2)
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.